Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics is a promising company with strong revenue growth and a successful product launch. However, potential risks such as competition and regulatory changes should be taken into consideration by investors before purchasing stock in the company.

Bears say

Beta Bionics is showing promising results in their Q1 report, reporting better-than-expected new patient additions, increased gross margin, and a progressing sales force expansion. However, there are concerns regarding competition from devices and therapeutics, potential risks associated with the clinical and regulatory processes for their future products, and reimbursement rate cuts. While their strategy of targeting the pharmacy channel may support future revenue growth, there is still a risk of slower sales force ramp and pharmacy access expansion. Additionally, their innovation pipeline includes a promising patch pump and bihormonal pump, but there are still concerns about unmet needs and competition in the market. Overall, there is potential for growth in the long term, but there are also risks and uncertainties that warrant a negative outlook on the stock at this time.

BBNX has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 10 analysts, BBNX has a Buy consensus rating as of May 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.